Myelodysplastic syndrome associated with chronic valproic acid therapy: a case report and review of the literature.
This report is of a case of myelodysplastic syndrome occurring in a 63 year old female on long-term valproic acid therapy for seizure disorder. Valproic acid therapy is widely prescribed for seizure disorders and is often associated with thrombocytopenia, macrocytic anemia and a reversible dysmyelopoiesis. There are rare reports in the literature of acute myeloid leukemia arising in patients treated with valproic acid. This case represents the first case report of a cytogenetically confirmed myelodysplastic syndrome occurring in a patient on long term valproic acid therapy and further supports that valproic acid, a histone deacetylase inhibitor, may be leukemogenic.
Allan
Robert W
RW
Department of Pathology, Immunology and Laboratory Medicine, University of Florida at Gainesville, Gainesville, FL, USA. allar@pathology.ufl.edu
D020732:Cytogenetic Analysis; D005260:Female; D056572:Histone Deacetylase Inhibitors; D006801:Humans; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000139:chemically induced* / Q000175:diagnosis; D012640:Seizures / Q000150:complications / Q000188:drug therapy; D014635:Valproic Acid / Q000009:adverse effects*
D056572:Histone Deacetylase Inhibitors; D014635:Valproic Acid